

# Prosthetic Joint Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/P43A66452290EN.html>

Date: December 2022

Pages: 54

Price: US\$ 2,000.00 (Single User License)

ID: P43A66452290EN

## Abstracts

Prosthetic Joint Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prosthetic Joint infections - Drugs In Development, 2022, provides an overview of the Prosthetic Joint infections (Musculoskeletal Disorders) pipeline landscape.

Prosthetic joint infection (PJI) is one of the most serious complications of prosthetic joint implantation. Symptoms include pain or stiffness in joints, swelling, redness around the wound, fatigue and fever. Risk factors include age, prior arthroplasty, poor nutritional status, obesity, diabetes mellitus and advanced HIV disease. Treatment includes antimicrobial therapy.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prosthetic Joint infections - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Prosthetic Joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Prosthetic Joint infections (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prosthetic Joint infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 2, 1, 7 and 1 respectively.

Prosthetic Joint infections (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Prosthetic Joint infections (Musculoskeletal Disorders).

The pipeline guide reviews pipeline therapeutics for Prosthetic Joint infections (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Prosthetic Joint infections (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Prosthetic Joint infections (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Prosthetic Joint infections (Musculoskeletal Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Prosthetic Joint infections (Musculoskeletal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Prosthetic Joint infections (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Prosthetic Joint infections - Overview
- Prosthetic Joint infections - Therapeutics Development Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Prosthetic Joint infections - Therapeutics Assessment
  - Assessment by Target
  - Assessment by Mechanism of Action
  - Assessment by Route of Administration
  - Assessment by Molecule Type
- Prosthetic Joint infections - Companies Involved in Therapeutics Development
  - Adaptive Phage Therapeutics Inc
  - Arietis Corp
  - Armata Pharmaceuticals Inc
  - ContraFect Corp
  - Integrated BioTherapeutics Inc
  - Lumobiotics GmbH
  - Osteal Therapeutics Inc
  - Peptilogics Inc
  - Pherecydes Pharma SA
  - Qentoros Inc
  - Sonoran Biosciences Inc
  - TenNor Therapeutics Ltd
- Prosthetic Joint infections - Drug Profiles
  - (tobramycin + vancomycin SR) - Drug Profile
    - Product Description
    - Mechanism Of Action
  - A-103 - Drug Profile
    - Product Description
    - Mechanism Of Action
  - APSA-02 - Drug Profile
    - Product Description
    - Mechanism Of Action
  - BIO-PLY - Drug Profile
    - Product Description

Mechanism Of Action

CF-296 - Drug Profile

Product Description

Mechanism Of Action

exebacase - Drug Profile

Product Description

Mechanism Of Action

PLG-0206 - Drug Profile

Product Description

Mechanism Of Action

PP-2351 - Drug Profile

Product Description

Mechanism Of Action

Prosthetic Joint Infection (PJI) - Drug Profile

Product Description

Mechanism Of Action

Small Molecule to Activate CIPP for Prosthetic Joint Infections - Drug Profile

Product Description

Mechanism Of Action

Small Molecules for Oncology and Infectious Disease - Drug Profile

Product Description

Mechanism Of Action

TNP-2092 - Drug Profile

Product Description

Mechanism Of Action

TPH-101 - Drug Profile

Product Description

Mechanism Of Action

Prosthetic Joint infections - Dormant Projects

Prosthetic Joint infections - Discontinued Products

Prosthetic Joint infections - Product Development Milestones

Featured News & Press Releases

Nov 29, 2022: Pherecydes Pharma announces the positive recommendation of the DSMB for the continuation of its phase II clinical study PhagoDAIR in osteoarticular infections caused by staphylococcus aureus

Nov 28, 2022: ContraFect announces ANSM approval of clinical trial application for exebacase in prosthetic joint infections

Oct 20, 2022: Peptilomics to present data at IDWeek 2022 on PLG0206, an engineered antimicrobial peptide targeting bacteria causing periprosthetic joint infection

Oct 07, 2022: Peptilogics doses first subject in periprosthetic joint infection trial

Sep 12, 2022: ContraFect announces presentation of new clinical data from a study using exebacase in the LysinDAIR procedure on patients with chronic knee prosthetic joint infection

Aug 06, 2022: Peptilogics to participate in Musculoskeletal Infection Society (MSIS) 32nd Annual Open Scientific Meeting in Pittsburgh

Aug 01, 2022: Armata Pharmaceuticals announces clearance of IND for prosthetic joint infections

Jul 19, 2022: Peptilogics receives FDA fast track designation for PLG0206, an investigational peptide therapeutic in development for the treatment of periprosthetic joint infection

Apr 19, 2022: Peptilogics to present data highlighting designed antimicrobial peptide for the treatment of Periprosthetic Joint Infection (PJI) at ECCMID 2022

Mar 22, 2022: Peptilogics' Presentations at American Academy of Orthopedic Surgeons (AAOS) 2022 Annual Meeting highlight peptide therapeutic PLG0206 for the treatment of periprosthetic joint infection (PJI)

Jan 10, 2022: Peptilogics announces FDA clearance of investigational new drug application to initiate clinical trial of PLG0206 in periprosthetic joint infection

Dec 01, 2021: Peptilogics announces two peer-reviewed publications on designed peptide therapeutic PLG0206 for periprosthetic joint infection

Sep 29, 2021: Peptilogics presents positive first-in-human phase 1 data for its lead engineered antibacterial peptide, PLG0206, at IDWeek 2021

Sep 22, 2021: Peptilogics to present first-in-human phase 1 clinical data of PLG0206 at IDWeek 2021

May 26, 2021: ContraFect announces multiple publications on exebacase, including first manuscript on local administration of lysin for potential treatment of prosthetic joint infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Prosthetic Joint infections, 2022  
Number of Products under Development by Companies, 2022  
Products under Development by Companies, 2022  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Prosthetic Joint infections - Pipeline by Adaptive Phage Therapeutics Inc, 2022  
Prosthetic Joint infections - Pipeline by Arietis Corp, 2022  
Prosthetic Joint infections - Pipeline by Armata Pharmaceuticals Inc, 2022  
Prosthetic Joint infections - Pipeline by ContraFect Corp, 2022  
Prosthetic Joint infections - Pipeline by Integrated BioTherapeutics Inc, 2022  
Prosthetic Joint infections - Pipeline by Lumobiotics GmbH, 2022  
Prosthetic Joint infections - Pipeline by Osteal Therapeutics Inc, 2022  
Prosthetic Joint infections - Pipeline by Peptilogics Inc, 2022  
Prosthetic Joint infections - Pipeline by Pherecydes Pharma SA, 2022  
Prosthetic Joint infections - Pipeline by Qentoros Inc, 2022  
Prosthetic Joint infections - Pipeline by Sonoran Biosciences Inc, 2022  
Prosthetic Joint infections - Pipeline by TenNor Therapeutics Ltd, 2022  
Prosthetic Joint infections - Dormant Projects, 2022  
Prosthetic Joint infections - Discontinued Products, 2022



## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Prosthetic Joint infections, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Prosthetic Joint Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/P43A66452290EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P43A66452290EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

